Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis
A Randomized, Double-blind, Positive-control and Placebo-controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety in Rupatifen Fumarate Capsules for the Seasonal Allergic Rhinitis Patients
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.
550 participants
Aug 18, 2026
INTERVENTIONAL
Conditions
Summary
This Phase Ⅲ randomized, double-blind, active- and placebo-controlled trial aims to assess the efficacy and safety of Rupatifen Fumarate Capsules for seasonal allergic rhinitis. Eligible participants will be randomized to Rupatifen Fumarate Capsules, Rupatadine Fumarate Tablets (active comparator), or matching placebo. All treatments are administered once daily at a consistent time with a 24 ± 2-hour interval between doses for 2 consecutive weeks.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral administration, one capsule once daily for 14 consecutive days
Oral administration, one tablet once daily for 14 consecutive days
Oral administration, one capsule once daily for 14 consecutive days
Oral administration, one tablet once daily for 14 consecutive days
Locations(18)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07711262